Gene therapy achieves high remission rates for aggressive leukemia

A new gene therapy shows promise against a rare, aggressive leukemia, achieving remission in 82% of patients. The BE-CAR7 therapy uses genetically edited T-cells from healthy donors to target and destroy T-cell acute lymphoblastic leukemia (T-ALL) in patients who previously failed other treatments. This advanced CAR-T cell therapy, utilizing base-editing technology, offers a potentially less toxic and more accessible treatment option for this difficult-to-treat cancer.